Moderate Mixed Aortic Valve Disease: Why Moderate Severity Carries Severe Risk

The Clinical Blind Spot: Redefining Moderate Mixed Aortic Valve Disease

In the management of valvular heart disease, clinical guidelines provide robust, evidence-based frameworks for the treatment of isolated severe aortic stenosis (AS) and severe aortic regurgitation (AR). However, a significant clinical grey area exists for patients presenting with moderate mixed aortic valve disease (MAVD)—the simultaneous presence of both moderate AS and moderate AR. Because neither lesion individually meets the threshold for ‘severe’ according to traditional echocardiographic criteria, these patients often fall into a surveillance gap where the cumulative hemodynamic burden is underestimated.

Recent evidence published in the European Heart Journal by Lopez Santi et al. (2026) sheds light on this high-risk population. By comparing the long-term outcomes of moderate MAVD against isolated severe AS and severe AR, the study provides a compelling argument for re-evaluating how we define ‘severity’ and when we should trigger surgical or transcatheter interventions.

Highlights of the Research

• Moderate MAVD is not a benign middle ground; its 10-year survival rate (62%) is significantly closer to that of isolated severe AS (55%) than to severe AR (79%).
• The presence of New York Heart Association (NYHA) class symptoms or a left ventricular ejection fraction (LVEF) below 50% identifies a subgroup of MAVD patients with a prognosis as poor as those with severe AS.
• Asymptomatic patients with moderate MAVD and preserved LVEF appear to have a clinical trajectory more aligned with severe AR, suggesting a window for close monitoring.
• The study advocates for the inclusion of symptomatic moderate MAVD or MAVD with LV dysfunction in the indications for aortic valve replacement (AVR).

Study Design and Methodology

The researchers conducted a comprehensive retrospective analysis across four international centers, including 1,926 patients. The cohort was categorized into three primary groups:

1. Moderate MAVD (n=527): Defined by moderate AS (mean gradient 20-39 mmHg or peak velocity 3.0-3.9 m/s) and moderate AR (standard echocardiographic criteria).
2. Severe AR (n=413): Isolated severe aortic regurgitation.
3. Severe AS (n=986): Isolated severe aortic stenosis.

The primary endpoint was all-cause mortality over a median follow-up of 7.2 years. To ensure clinical relevance, the investigators utilized multivariable Cox proportional hazards models, adjusting for key covariates such as age, sex, comorbidities, LVEF, and NYHA functional class. Critically, AVR was analyzed as a time-dependent covariate to account for the impact of surgical or transcatheter intervention during the follow-up period.

Key Findings: The ‘Double Hit’ of Pressure and Volume Overload

Survival Disparities

The most striking finding was the survival curve of the moderate MAVD group. While clinicians might intuitively place ‘moderate’ mixed disease at a lower risk than ‘severe’ isolated disease, the data proved otherwise. The 10-year survival for moderate MAVD was 62%. This was statistically similar to the 55% observed in severe AS (P = .09) but significantly worse than the 79% observed in severe AR (P < .001). This suggests that the combination of pressure overload (from AS) and volume overload (from AR) exerts a synergistic deleterious effect on the myocardium.

The Impact of Symptoms and LV Function

The study further stratified moderate MAVD patients based on the traditional triggers for AVR in severe disease.

For symptomatic patients, the adjusted mortality for moderate MAVD was comparable to that of symptomatic severe AS. This indicates that once a patient with moderate MAVD develops symptoms, their risk profile escalates to that of the highest-risk valvular patients. Conversely, asymptomatic moderate MAVD patients had survival rates similar to the severe AR group (both symptomatic and asymptomatic).

Regarding left ventricular function, MAVD patients with an LVEF < 50% faced a mortality risk nearly identical to that of severe AS patients with similar LV dysfunction. In contrast, those with preserved LVEF (≥ 50%) followed a survival path more similar to that of severe AR, regardless of whether the AR patients had LV dysfunction or not.

Mechanistic Insights: Why Mixed Disease is Different

The pathophysiology of MAVD is unique. In isolated AS, the left ventricle (LV) undergoes concentric hypertrophy to overcome pressure. In isolated AR, the LV undergoes eccentric hypertrophy to accommodate volume. In MAVD, the heart must adapt to both. This ‘double hit’ leads to a more rapid progression of LV remodeling, fibrosis, and eventual failure. The mean gradient in moderate MAVD may not reach the 40 mmHg threshold of ‘severe’ AS, but because the stroke volume is often increased due to the regurgitant fraction, the total workload of the LV is much higher than the gradient alone suggests.

Expert Commentary and Clinical Implications

Currently, the AHA/ACC and ESC guidelines provide class I recommendations for AVR in symptomatic severe AS or AR, and in asymptomatic patients with LVEF 40 mmHg) may result in missing the optimal window for intervention, leading to irreversible myocardial damage and increased mortality.

However, limitations must be noted. This was a retrospective study, and the determination of ‘moderate’ AR can be technically challenging and subject to inter-observer variability. Furthermore, the decision to perform AVR was left to the treating physicians, which may introduce selection bias. Randomized controlled trials focusing specifically on intervention timing for MAVD are needed to formalize these findings into future guidelines.

Conclusion

Moderate mixed aortic valve disease is a high-risk condition that warrants closer attention than its ‘moderate’ label suggests. The data from Lopez Santi et al. provide a clear signal: when moderate MAVD is accompanied by symptoms or a decline in LVEF, it behaves like severe aortic stenosis. Clinicians should consider a more proactive approach to aortic valve replacement in these patients to mitigate the significant long-term mortality risk associated with this complex valvular pathology.

References

1. Lopez Santi P, Bernard J, Chua A, et al. Outcomes of moderate mixed aortic valve stenosis and regurgitation. European Heart Journal. 2026;47(11):1357-1367. PMID: 41104570.
2. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143(5):e35-e71.
3. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2022;43(7):561-632.